Oxford Bioscience Partners is an early-stage venture capital investment firm that invests in life sciences and healthcare sectors with a focus on technology, medical devices, instruments and systems, and therapeutics companies. It was established in 1992 by Cornelius T. Ryan and Edmund M. Olivier.
Oxford Biosciences Partners has approximately $1B of committed capital under management. It has invested in over 140 life science companies worldwide, including Yolia Health, CardioFocus, Affinium Pharmaceuticals, Mitralign, and Seahorse Bioscience.
A company ofering analytical, biomanufacturing and consumable labware products for biological research and drug discovery applications
A company focused on the discovery and development of treatments for rare inherited diseases.
A company developing tools and ablation treatment for atrial fibrillation
A company developing vaccines for flu, malaria, dengue, papillomavirus and respiratory syncytial virus
A company focused on the development and manufacturing of specialty biopharmaceutical products.
A biotechnology company that produces natural gas using microorganisms
A company developing orally bioavailable small molecule macrocyclic compounds to disrupt protein-protein interactions
A company developing pharmaceuticals to treat metabolic disease
A pharmaceutical company developing drugs for the treatment of various cancers
A metabolomics company developing molecular gastronomy kits for evaluating normal biologic functions
A biotechnology developing drug to stimulate the growth of new neurons
Mitralign is a Tewksbury, Massachusetts-based company.
Melinta Therapeutics is a New Haven, Connecticut-based company.